Growth factor receptors are the most successful drug target class in oncology — EGFR inhibitors (osimertinib), HER2 antibodies (trastuzumab, trastuzumab deruxtecan), and VEGF pathway blockers (bevacizumab) together generate over $40 billion in annual sales. For drug discovery teams, recombinant growth factor ligands and receptor proteins are the workhorse reagents behind binding assays, resistance screening, and cell-based potency testing. This article maps the three core pathways and the reagents each workflow requires.
EGFR/ErbB Family: The Precision Medicine Backbone
EGFR (ErbB1) and HER2 (ErbB2) drive proliferation in lung, colorectal, breast, and gastric cancers. Activating EGFR mutations (L858R, exon 19 deletions) define patient populations for first-line TKIs, while acquired mutations (T790M, C797S) drive resistance — a cycle that requires continuous screening against new variants. HER2 remains the most targeted receptor in solid tumors, with antibody-drug conjugates (trastuzumab deruxtecan) redefining treatment in HER2-low breast cancer.
Core reagents: recombinant EGF and EGFR extracellular domains for binding and phosphorylation assays; HER2 proteins for ADC binding and internalization studies.
VEGFR: The Angiogenesis Axis
VEGF-A binding to VEGFR-2 activates endothelial cell proliferation, migration, and permeability — the core of tumor angiogenesis. Anti-VEGF therapy (bevacizumab) and VEGFR TKIs (sunitinib, lenvatinib) starve tumors of blood supply. Resistance mechanisms — FGF-2 upregulation, vessel co-option, pericyte coverage — have driven research into combination strategies. Recombinant VEGF-A powers tube formation assays; VEGFR-2 extracellular domains are standard in inhibitor binding screens (SPR and ELISA formats).
FGFR: The Emerging Target Class
FGFR fusions and amplifications occur in bladder cancer, cholangiocarcinoma, and gastric cancer. Approved FGFR inhibitors (erdafitinib, pemigatinib) validated the class, and on-target resistance mutations (FGFR2 V564F) are now active research areas. FGF-2 and FGF receptor proteins support proliferation assays and kinase inhibitor profiling.
Resistance Mechanisms Every Program Must Screen
| Pathway | Primary mutations | Resistance mutations | Key assays |
|---|---|---|---|
| EGFR | L858R, exon 19 del | T790M, C797S, MET amplification | Kinase inhibition, cell viability, phosphorylation (WB) |
| HER2 | Amplification | Trastuzumab-resistant variants | ADC binding, internalization, cytotoxicity |
| FGFR | FGFR2/3 fusions | V564F, N549K gatekeeper | Kinase panel screening |
| VEGFR | — | FGF-2 upregulation, vessel co-option | Tube formation, endothelial proliferation |
Reagents for Each Drug Discovery Workflow
- Ligand stimulation assays: active EGF, VEGF-A, FGF-2 with verified ED50 values — for receptor phosphorylation and downstream signaling readouts
- Binding and SPR: receptor extracellular domains (EGFR, VEGFR-2, FGFR1–4) in His- or Avi-tagged formats for oriented immobilization
- Cell-based potency: growth factors in carrier-free, low-endotoxin formats for reproducible dose-response curves
- In vivo pharmacology: carrier-free, endotoxin-tested proteins suitable for animal models
BioCrest Sci supplies 250+ recombinant growth factors and receptors covering the EGFR, VEGFR, and FGFR families, with custom production available for difficult targets.
FAQ
Why is my EGFR phosphorylation assay inconsistent?
Check ligand bioactivity (ED50), serum starvation duration (typically 16–24 h), and the EGF lot — ligand activity, not antibody quality, is the most common source of variability.
Do I need mammalian-expressed receptors for SPR?
For binding assays, receptor ECDs expressed in mammalian cells preserve disulfide-dependent folding. E. coli-expressed ECDs are acceptable for peptide epitope work but can misfold for conformational epitopes.
References
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.
- Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795-803.
By BioCrest Sci Research Team. Last reviewed August 2026.
Explore the Growth Factors resource hub or contact sales@biocrestsci.com to discuss your screening program.